437 related articles for article (PubMed ID: 20811458)
1. Gamma-secretase activating protein is a therapeutic target for Alzheimer's disease.
He G; Luo W; Li P; Remmers C; Netzer WJ; Hendrick J; Bettayeb K; Flajolet M; Gorelick F; Wennogle LP; Greengard P
Nature; 2010 Sep; 467(7311):95-8. PubMed ID: 20811458
[TBL] [Abstract][Full Text] [Related]
2. Pharmacological modulation of GSAP reduces amyloid-β levels and tau phosphorylation in a mouse model of Alzheimer's disease with plaques and tangles.
Chu J; Lauretti E; Craige CP; Praticò D
J Alzheimers Dis; 2014; 41(3):729-37. PubMed ID: 24662099
[TBL] [Abstract][Full Text] [Related]
3. The role of γ-secretase activating protein (GSAP) and imatinib in the regulation of γ-secretase activity and amyloid-β generation.
Hussain I; Fabrègue J; Anderes L; Ousson S; Borlat F; Eligert V; Berger S; Dimitrov M; Alattia JR; Fraering PC; Beher D
J Biol Chem; 2013 Jan; 288(4):2521-31. PubMed ID: 23209290
[TBL] [Abstract][Full Text] [Related]
4. Modulation of amyloid precursor protein cleavage by γ-secretase activating protein through phase separation.
Jin C; Wang J; Wang Y; Jia B; Guo X; Yang G; Xu P; Greengard P; Zhou R; Shi Y
Proc Natl Acad Sci U S A; 2022 Mar; 119(12):e2122292119. PubMed ID: 35298330
[TBL] [Abstract][Full Text] [Related]
5. Immunohistochemical characterization of γ-secretase activating protein expression in Alzheimer's disease brains.
Satoh J; Tabunoki H; Ishida T; Saito Y; Arima K
Neuropathol Appl Neurobiol; 2012 Apr; 38(2):132-41. PubMed ID: 21718343
[TBL] [Abstract][Full Text] [Related]
6. GSAP modulates γ-secretase specificity by inducing conformational change in PS1.
Wong E; Liao GP; Chang JC; Xu P; Li YM; Greengard P
Proc Natl Acad Sci U S A; 2019 Mar; 116(13):6385-6390. PubMed ID: 30850537
[TBL] [Abstract][Full Text] [Related]
7. Degradation of gamma secretase activating protein by the ubiquitin-proteasome pathway.
Chu J; Li JG; Hoffman NE; Madesh M; Praticò D
J Neurochem; 2015 May; 133(3):432-9. PubMed ID: 25533523
[TBL] [Abstract][Full Text] [Related]
8. Gamma secretase-activating protein is a substrate for caspase-3: implications for Alzheimer's disease.
Chu J; Li JG; Joshi YB; Giannopoulos PF; Hoffman NE; Madesh M; Praticò D
Biol Psychiatry; 2015 Apr; 77(8):720-8. PubMed ID: 25052851
[TBL] [Abstract][Full Text] [Related]
9. Rac1 changes the substrate specificity of gamma-secretase between amyloid precursor protein and Notch1.
Boo JH; Sohn JH; Kim JE; Song H; Mook-Jung I
Biochem Biophys Res Commun; 2008 Aug; 372(4):913-7. PubMed ID: 18538664
[TBL] [Abstract][Full Text] [Related]
10. Tracing the GSAP-APP C-99 Interaction Site in the β-Amyloid Pathway Leading to Alzheimer's Disease.
Angira D; Chikhale R; Mehta K; Bryce RA; Thiruvenkatam V
ACS Chem Neurosci; 2019 Aug; 10(8):3868-3879. PubMed ID: 31299145
[TBL] [Abstract][Full Text] [Related]
11. A novel gamma -secretase assay based on detection of the putative C-terminal fragment-gamma of amyloid beta protein precursor.
Pinnix I; Musunuru U; Tun H; Sridharan A; Golde T; Eckman C; Ziani-Cherif C; Onstead L; Sambamurti K
J Biol Chem; 2001 Jan; 276(1):481-7. PubMed ID: 11035007
[TBL] [Abstract][Full Text] [Related]
12. Proton myo-inositol cotransporter is a novel γ-secretase associated protein that regulates Aβ production without affecting Notch cleavage.
Teranishi Y; Inoue M; Yamamoto NG; Kihara T; Wiehager B; Ishikawa T; Winblad B; Schedin-Weiss S; Frykman S; Tjernberg LO
FEBS J; 2015 Sep; 282(17):3438-51. PubMed ID: 26094765
[TBL] [Abstract][Full Text] [Related]
13. Oxidative lipid modification of nicastrin enhances amyloidogenic γ-secretase activity in Alzheimer's disease.
Gwon AR; Park JS; Arumugam TV; Kwon YK; Chan SL; Kim SH; Baik SH; Yang S; Yun YK; Choi Y; Kim S; Tang SC; Hyun DH; Cheng A; Dann CE; Bernier M; Lee J; Markesbery WR; Mattson MP; Jo DG
Aging Cell; 2012 Aug; 11(4):559-68. PubMed ID: 22404891
[TBL] [Abstract][Full Text] [Related]
14. Gleevec increases levels of the amyloid precursor protein intracellular domain and of the amyloid-beta degrading enzyme neprilysin.
Eisele YS; Baumann M; Klebl B; Nordhammer C; Jucker M; Kilger E
Mol Biol Cell; 2007 Sep; 18(9):3591-600. PubMed ID: 17626163
[TBL] [Abstract][Full Text] [Related]
15. Pharmacological characterization of the novel γ-secretase modulator AS2715348, a potential therapy for Alzheimer's disease, in rodents and nonhuman primates.
Mitani Y; Akashiba H; Saita K; Yarimizu J; Uchino H; Okabe M; Asai M; Yamasaki S; Nozawa T; Ishikawa N; Shitaka Y; Ni K; Matsuoka N
Neuropharmacology; 2014 Apr; 79():412-9. PubMed ID: 24373902
[TBL] [Abstract][Full Text] [Related]
16. Gleevec shifts APP processing from a β-cleavage to a nonamyloidogenic cleavage.
Netzer WJ; Bettayeb K; Sinha SC; Flajolet M; Greengard P; Bustos V
Proc Natl Acad Sci U S A; 2017 Feb; 114(6):1389-1394. PubMed ID: 28115709
[TBL] [Abstract][Full Text] [Related]
17. Regulation of gamma-secretase activating protein by the 5Lipoxygenase: in vitro and in vivo evidence.
Chu J; Li JG; Hoffman NE; Stough AM; Madesh M; Praticò D
Sci Rep; 2015 Jun; 5():11086. PubMed ID: 26076991
[TBL] [Abstract][Full Text] [Related]
18. gamma-Secretase heterogeneity in the Aph1 subunit: relevance for Alzheimer's disease.
Serneels L; Van Biervliet J; Craessaerts K; Dejaegere T; Horré K; Van Houtvin T; Esselmann H; Paul S; Schäfer MK; Berezovska O; Hyman BT; Sprangers B; Sciot R; Moons L; Jucker M; Yang Z; May PC; Karran E; Wiltfang J; D'Hooge R; De Strooper B
Science; 2009 May; 324(5927):639-42. PubMed ID: 19299585
[TBL] [Abstract][Full Text] [Related]
19. An NSAID-like compound, FT-9, preferentially inhibits gamma-secretase cleavage of the amyloid precursor protein compared to its effect on amyloid precursor-like protein 1.
Sala Frigerio C; Kukar TL; Fauq A; Engel PC; Golde TE; Walsh DM
Biochemistry; 2009 Nov; 48(46):10894-904. PubMed ID: 19821615
[TBL] [Abstract][Full Text] [Related]
20. BIIB042, a novel γ-secretase modulator, reduces amyloidogenic Aβ isoforms in primates and rodents and plaque pathology in a mouse model of Alzheimer's disease.
Scannevin RH; Chollate S; Brennan MS; Snodgrass-Belt PA; Peng H; Xu L; Jung MY; Bussiere T; Arastu MF; Talreja T; Xin Z; Dunstan RW; Fahrer D; Rohde E; Dunah AW; Wang J; Kumaravel G; Taveras AG; Moore Arnold H; Rhodes KJ
Neuropharmacology; 2016 Apr; 103():57-68. PubMed ID: 26690893
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
